CQP(SZ:000950) 智通财经网·2025-12-10 12:04Core Viewpoint - Chongqing Pharmaceutical (Group) Co., Ltd., a subsidiary of Zhongyao Holdings, has granted Pfizer exclusive rights to develop, use, produce, and commercialize the oral small molecule GLP-1 receptor agonist YP05002 and related products globally for human and animal indications [1] Group 1 - Zhongyao Holdings holds a 38.67% stake in Yaoyou Pharmaceutical, which is involved in the licensing agreement with Pfizer [1] - The agreement includes an upfront non-refundable payment of $150 million and potential milestone payments of up to $350 million based on clinical and commercialization progress [1] - YP05002 is developed by Yaoyou Pharmaceutical and is designed to treat type 2 diabetes, obesity, and related diseases through various mechanisms, including insulin secretion enhancement and appetite suppression [1] Group 2 - The potential indications for YP05002 include long-term weight management, type 2 diabetes, and metabolic dysfunction-related fatty liver disease [1]